Parkside Financial Bank & Trust Buys 2,370 Shares of Eli Lilly and Company (NYSE:LLY)

Parkside Financial Bank & Trust lifted its stake in Eli Lilly and Company (NYSE:LLY) by 93.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,898 shares of the company’s stock after buying an additional 2,370 shares during the period. Parkside Financial Bank & Trust’s holdings in Eli Lilly and Company were worth $2,855,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in LLY. Simon Quick Advisors LLC raised its position in Eli Lilly and Company by 10.5% during the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after purchasing an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $363,000. WASHINGTON TRUST Co raised its position in Eli Lilly and Company by 16.5% during the fourth quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after purchasing an additional 2,671 shares in the last quarter. Liontrust Investment Partners LLP acquired a new position in Eli Lilly and Company during the third quarter valued at approximately $8,326,000. Finally, Assenagon Asset Management S.A. raised its position in Eli Lilly and Company by 4.0% during the third quarter. Assenagon Asset Management S.A. now owns 474,940 shares of the company’s stock valued at $255,105,000 after purchasing an additional 18,079 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

LLY traded down $11.77 on Wednesday, hitting $733.92. The company’s stock had a trading volume of 526,087 shares, compared to its average volume of 3,017,458. The company’s 50 day simple moving average is $763.89 and its 200-day simple moving average is $664.05. The firm has a market cap of $697.34 billion, a P/E ratio of 128.56, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $370.68 and a 12 month high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period last year, the firm earned $2.09 EPS. Analysts forecast that Eli Lilly and Company will post 12.52 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Bank of America upped their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Barclays upped their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research note on Wednesday, February 21st. Finally, Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $728.05.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.